| Outcome Measures: |
Primary: The safety of a 5 mg dose of COR-001 as measured by the incidence of adverse events, To evaluate the safety of a 5 mg dose of COR-001 delivered subcutaneously, 1 month after the 4th patient has received study drug|The safety of a 15 mg dose of COR-001 as measured by the incidence of adverse events, To evaluate the safety of a 15 mg dose of COR-001 delivered subcutaneously, 1 month after the 4th patient has received study drug|The safety of a 50 mg dose of COR-001 as measured by the incidence of adverse events, To evaluate the safety of a 50 mg dose of COR-001 delivered subcutaneously, 1 month after the 4th patient has received study drug|The safety of a 100 mg dose of COR-001 as measured by the incidence of adverse events, To evaluate the safety of a 100 mg dose of COR-001 delivered subcutaneously, 1 month after the 4th patient has received study drug | Secondary: Pharmacokinetic analysis: maximum serum drug concentrations (Cmax), To evaluate single-dose pharmacokinetics of COR-001 delivered subcutaneously, Pre-dose, 4 hours post-dose, and days 2-7, 11, 15, 22, 29, 57, 85, 141, and 225 post-dose.|Pharmacokinetic analysis: area under the serum drug concentration-time curve (AUC), To evaluate the single-dose pharmacokinetics of COR-001 delivered subcutaneously, Pre-dose, 4 hours post-dose, and days 2-7, 11, 15, 22, 29, 57, 85, 141, and 225 post-dose.|Pharmacokinetic analysis: terminal elimination half-life (t1/2), To evaluate the single-dose pharmacokinetics of COR-001 delivered subcutaneously, Pre-dose, 4 hours post-dose, and days 2-7, 11, 15, 22, 29, 57, 85, 141, and 225 post-dose.|The effectiveness of COR-001 as measured by levels of an inflammatory marker, To evaluate the effectiveness of COR-001 as measured by CRP levels., Screening and at weeks 1 - 5, 8, 12, 20, and 32.
|
